Aurobindo Pharma has expanded its global presence by establishing a new wholly-owned subsidiary in Malaysia. The new entity, named Aurobindo Pharma (Malaysia) SDN. BHD., was incorporated on September 17, 2025. This strategic move will facilitate the expansion of the company’s pharmaceutical product business in the Malaysian market. The initial investment in the subsidiary is RM 400,000 (approximately USD 100,000).
Subsidiary Incorporation Details
Aurobindo Pharma, through its subsidiary Helix Healthcare B.V., has incorporated a new wholly-owned subsidiary in Malaysia named Aurobindo Pharma (Malaysia) SDN. BHD. The date of incorporation is September 17, 2025. This marks a strategic step to further expand the company’s global operations and market reach.
Financial Investment
The initial investment in the new Malaysian subsidiary amounts to RM 400,000, which is equivalent to approximately USD 100,000. This investment covers the subscription to the share capital, divided into 400,000 shares, each with a nominal value of RM 1.00.
Strategic Rationale
The primary objective for establishing Aurobindo Pharma (Malaysia) SDN. BHD. is to expand Aurobindo Pharma’s business in Malaysia. This new entity will focus on growing the presence and distribution of the company’s pharmaceutical products within the Malaysian market.
Source: BSE
